TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Linifanib (ABT-869) in Combination With Carboplatin/Paclitaxel in Japanese Subjects With Non-Small Cell Lung Cancer (NSCLC)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* The subject must be 20 and older years of age.~* The subject must have cytologically or histologically confirmed non-squamous NSCLC. Subjects may have a mixed histology but must be predominantly non-squamous to be eligible.~* The subject must have advanced or metastatic (Stage IV \[According to American Joint Committee on Cancer (AJCC) staging manual, 7th edition\]) disease that is not amenable to surgical resection or radiation with curative intent.~* The subject must have not received prior chemotherapy for NSCLC.~* The subject has measurable disease, defined as at least 1 unidimensionally measurable lesion on a CT scan as defined by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.~* The subject has an Easter Cooperative Oncology Group (ECOG) Performance Score of 0-1.~* The subject must have adequate bone marrow, renal and hepatic function.~Exclusion Criteria~* The subject has hypersensitivity to paclitaxel or to other drugs formulated with polyethoxylated castor oil (Cremophor).~* The subject has received any anti-cancer therapy for treatment of NSCLC including investigational agents, immunotherapy, traditional Chinese medicine/herbal remedies, hormonal, targeted agents (i.e., erlotinib, imatinib), biologic therapy or cytotoxic chemotherapy (i.e., alkylating agents, microtubule inhibitors, antimetabolites).~* The subject has a history of another active cancer within the past 5 years except cervical cancer in situ, in situ carcinoma of the bladder, squamous cell or basal cell carcinoma of the skin.~* The subject has active ulcerative colitis, Crohn's disease, celiac disease or any other conditions that interfere with absorption.~* The subject has a medical condition, which in the opinion of the study investigator places them at an unacceptably high risk for toxicities.~* The subject is pregnant or breast feeding.~* The subject has NSCLC with a predominant squamous cell histology.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): None
- Arm B (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clear clinical and laboratory diagnosis of HAE~* Baseline plasma level of functional C1INH of less than 50% of normal~* Evidence for exacerbation or development of a severe abdominal, oro-facial/ pharyngeal/ laryngeal, genito-urinary and/or peripheral HAE attack~Exclusion Criteria:~* Acquired angioedema~* Pregnancy or breastfeeding~* Participation in another clinical study within prior 3 months

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 100 IU/kg rhC1INH (Type: EXPERIMENTAL): 100 IU/kg recombinant human C1 inhibitor
- Saline (Type: PLACEBO_COMPARATOR): Saline solution

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-911 in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male aged 18 to 45 years with a body mass index (BMI) between 18 and 30 kg/m2, (inclusive).~Exclusion Criteria:~* Standard exclusion criterion for Phase 1 clinical trial in healthy subjects:~  * History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the volunteer at risk because of participation in the study, or influence the results or the volunteer's ability to participate.~ * History or presence of gastro intestinal (GI), hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs as judged by Investigator.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Single ascending dose (Type: ACTIVE_COMPARATOR): Single dose of SUVN-911 or placebo in healthy male subjects
- Multiple ascending dose (Type: ACTIVE_COMPARATOR): Multiple doses of SUVN-911 or placebo in healthy male subjects

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of ETC-1002 in Participants With Hypercholesterolemia and Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Mean 24-hour ambulatory SBP greater than or equal to 130 mmHg~* or- Mean 24-hour ambulatory DBP greater than or equal to 80 mmHg~* Fasting LDL-C between 100 and 220 mg/dL~* Fasting triglycerides less than 400 mg/dL~* Body mass index (BMI) between 18 and 45 kg/m2~Exclusion Criteria:~* Known or suspected secondary hypertension or history of malignant hypertension~* Taking more than two anti-hypertension medications at the first visit~* History or current clinically significant cardiovascular disease~* History or current type 1 diabetes or type 2 diabetes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- ETC-1002 (Type: EXPERIMENTAL): ETC-1002 180 mg/day
- Placebo (Type: PLACEBO_COMPARATOR): Placebo control

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Aqueous Humor Dynamics and Brimonidine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must be 19 years of age or older~* Subjects must exhibit a history of untreated IOPs between 21 and 35 mmHg (inclusive)~Exclusion Criteria:~* Age less than nineteen years old~* Women who are pregnant, lactating or of childbearing potential who are not using birth control measures.~* Aphakia or pseudophakia~* Best corrected visual acuity worse than 20/60 in either eye~* Chronic or recurrent severe ocular inflammatory disease~* Ocular infection or inflammation within (3) months of screening visit.~* History of clinically significant or progressive retinal disease such as retinal degeneration, diabetic retinopathy or retinal detachment.~* Any abnormality preventing reliable tonometry of either eye.~* Previous exposure to: beta-adrenergic antagonists, topical prostaglandin analogues within six (6) weeks of the baseline visit; α-adrenergic agonists within two (2) weeks of the baseline visit; and cholinergic agonists and carbonic anhydrase inhibitors within five (5) days of the treatment initiation visit.~* History of any severe ocular pathology (including severe dry eye) that would prelude the administration of a topical beta blocker, carbonic anhydrase inhibitor, or a topical prostaglandin.~* Any eye with a cup-to-disc ratio greater than 0.8.~* History of intraocular surgery~* History of ocular laser surgery~* History of severe or serious hypersensitivity to brimonidine or its vehicle.~* History of severe, unstable, or uncontrolled cardiovascular, hepatic or renal disease.~* History of bronchial asthma or chronic obstructive pulmonary disease (COPD).~* Less than one month (prior to baseline) stable dosing regimen of any non-glaucoma medication that would affect IOP.~* Gonioscopy angle \< 2.~* Inability to be dosed with treatment medication~* Inability to discontinue contact lens wear.~* Therapy with any investigational agent within 30 days of screening.~* Use of any additional topical or systemic adjunctive ocular hypotensive medications during the study.~* History of open angle glaucoma (either primary open angle glaucoma or other cause of open angle glaucoma) or narrow angle glaucoma.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intraocular pressure lowering drug (Type: ACTIVE_COMPARATOR): Eyedrops for lowering intraocular pressure
- Artificial Tears (Type: PLACEBO_COMPARATOR): Lubricated eye drops

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
ENTRY CRITERIA:~DISEASE CHARACTERISTICS:~* Locally advanced or metastatic malignancies~* Histologically or cytologically confirmed~* Evaluable~* Surgically and medically incurable~* Not responding to standard therapy or no other standard therapy exists~* Human leukocyte antigen (HLA)-A2.1/p53 positive~PRIOR/CONCURRENT THERAPY:~* No prior Proleukin therapy within one year~* No concurrent radiotherapy, chemotherapy, or other immunotherapy~* More than 4 weeks since prior major radiotherapy~* More than 4 weeks since prior cytotoxic therapy~* More than 6 weeks since prior nitrosoureas therapy~* More than 8 weeks since prior monoclonal antibody therapy~PATIENT CHARACTERISTICS:~Life expectancy~* \> 3 months~Performance status~* Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1~Bone marrow reserve~* Absolute neutrophil count (AGC/ANC) ≥ 1,500/microliters (uL)~* Platelets ≥100,000/uL~* Hemoglobin ≥ 10g/dL~Renal function~* Serum creatinine ≤ 1.5 X Upper limit of normal (ULN)~Hepatic function~* Total bilirubin ≤ 1.5 X ULN~* Aspartate Aminotransferase (AST) ≤ 2.5 X ULN~* Alkaline phosphatase ≤ 2.5 X ULN~* Prothrombin time (PT) or international normalized ratio (INR) ≤ 1.5 X ULN~* Activated partial thromboplastin time (aPTT) ≤ 1.5 X ULN~Cardiovascular~* May be safely tapered off anti-hypertensives if currently on anti-hypertensives~* New York Heart Association classification I or II~* No congestive heart failure \<6 months~* No unstable angina pectoris \<6 months~* No myocardial infarction \<6 months~* No history of ventricular arrhythmias~* Normal cardiac stress test required if any of the following is present:~  * Over age 50~ * History of abnormal EKG~ * Symptoms of cardiac ischemia or arrhythmia~Pulmonary~* Normal pulmonary function test (FEV1 ≥ 75% of predicted value) if any of the following is present:~  * Prolonged history of cigarette smoking~ * Symptoms of respiratory dysfunction~Other~* No known autoimmune disease~* No known HIV positive~* No psychiatric illness/social situations that would limit study compliance~* No history or evidence of central nervous system (CNS) disease~* No active systemic infection requiring parental antibiotic therapy~* No systemic steroid therapy required~* No prior organ allograft~* Not receiving other investigational agents~* Not receiving chronic medication for asthma~* Not pregnant or nursing~* Fertile patients must use effective contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of TRC101 in Subjects With Metabolic Acidosis Associated With Chronic Kidney Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Blood bicarbonate level of 12 to 20 mEq/L.~* Estimated glomerular filtration rate (eGFR) of 20 to 40 mL/min/1.73m2.~* Stable kidney function defined as \<=20% variability in eGFR during screening period.~Key Exclusion Criteria:~* Any level of low blood bicarbonate during the screening period that in the opinion of the Investigator, requires emergency intervention or evaluation for an acute acidotic process.~* Anuria, dialysis, acute kidney injury, or history of acute kidney insufficiency within 3 months prior to screening.~* Heart failure with maximum New York Heart Association (NYHA) Class IV symptoms or that required hospitalization during the preceding 6 months.~* Heart or kidney transplant.~* Chronic obstructive pulmonary disease (COPD) that is treated with chronic oral steroids, that requires the subject to be on oxygen, or that required hospitalization within the previous 6 months.~* Change in doses to alkali therapy in the 4 weeks prior to screening.~* History or current diagnosis of diabetic gastroparesis, bowel obstruction, swallowing disorders, inflammatory bowel disease, major gastrointestinal surgery, frequent diarrhea or active gastric/duodenal ulcers.~* Serum calcium \<= 8.0 mg/dL at screening.~* Planned initiation of renal replacement therapy within 12 weeks following randomization.~* Use of polymeric binder drugs within 14 days prior to screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- TRC101 (Type: EXPERIMENTAL): Administered once daily (QD) for 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Administered once daily (QD) for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Relapses in Plasmodium Ovale and Efficacy of Artemether-lumefantrine for Mixed Species and Non-falciparum Malaria

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients older than 1 year~* Presence of uncomplicated malaria infection confirmed by: fever or history of fever in the previous 3 days, and positive microscopy of P. malariae, P. ovale or mixed infection with parasite density \> 10 - 200000/µl of blood~* Residence in vicinity and no travel plans for the next 6 months~* Written informed consent by the patient or the legal representative and where possible, patient assent will be sought. If the patient/parent/guardian is unable to write, witnessed consent is permitted according to local ethical considerations.~Exclusion Criteria:~* Presence of P. falciparum monoinfection~* Presence of severe malaria (clinical WHO criteria)~* Presence of other febrile conditions~* Known history of hypersensitivity, allergic or adverse reactions to artemether or lumefantrine~* Intake of any antimalarials or antibiotics with known antimalarial activity in the past 72 hours~* Intake of an 8-aminoquinoline antimalarial or atovaquone-proguanil in preceding 28 days~* Pregnant women in first trimenon

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Coartem (Type: OTHER): Patients will receive the study drug combination artemether-lumefantrine (Coartem®) orally as a 6 dose regimen for three consecutive days. Tablets are available as a fixed dose combination of 20mg artemether plus 120mg lumefantrine. The dosing will be based on the body weight and follow the manufacturer's recommendations:~Body weight 5-14kg: 1 tablet; Body weight 15-24kg: 2 tablets; Body weight 25-34kg: 3 tablets; Body weight \> 34kg: 4 tablets; The respective amount of tablets is to be taken at hours 0, 8, 24, 36, 48 and 60 with fatty food.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bioequivalence Study Evaluating the Pharmacokinetics of DMB-3111 and Trastuzumab in Healthy Japanese Male Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy Japanese male adults~2. Body Mass Index (BMI) between 17.6 and 26.4 kg/m² at the time of screening BMI = Body Weight (kg)/\[Height (m)\]²~3. The individual who freely consents to participate after receiving a detailed explanation of the clinical study and completely understanding thereof, and who has capacity to follow precautions and provide written consent.~Exclusion Criteria:~1. History of hypersensitivity to components of Trastuzumab or diphenhydramine or any other drug~2. Use of any ethical drug within 2 weeks before investigational product administration or any over-the-counter drug within 1 week before investigational product administration that would affect study participation in the opinion of the investigator or subinvestigators (except for diphenhydramine, which will be used concomitantly in the present clinical trial and any drug applied locally and having no systemic actions)~3. History of allergic symptoms such as bronchial asthma and urticaria that would affect study participation in the opinion of the investigator or subinvestigators~4. History of cardiac disorders, hypertension, coronary artery disease (e.g., myocardial infarction, angina), and/or vascular disorder; ongoing palpitations, shortness of breath, and/or tachycardia

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: 39 Years
- Healthy Volunteers: t

Study Arms:
- DMB-3111 (Type: EXPERIMENTAL): 6 mg/kg is once given in intravenous drip infusion taking 90 min
- trastuzumab (Type: ACTIVE_COMPARATOR): 6 mg/kg is once given in intravenous drip infusion taking 90 min

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: School-Based Treatment With ACT to Reduce Transmission

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
For IPT intervention~Inclusion Criteria:~1. Student enrolled in a participating intervention school.~2. Willingness of parent/guardian to provide written informed consent.~3. Provision of written assent by the student (aged 8 years or above).~Exclusion Criteria:~1. Age \< 5 years~2. Known allergy or history of adverse reaction to DP~3. Menarche in female students~4. Weight \< 11 kg~5. History of cardiac problems or fainting~6. Family history of long QT syndrome~7. Current use of medications known to prolong the QT interval~8. Not able to locate parent or guardian, after at least three attempts including parent/teacher association (PTA) meetings and home visits~9. Not able to locate the student at school, after at least three attempts

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Intermittent preventive treatment (IPT) (Type: EXPERIMENTAL): Dihydroartemisinin-piperaquine (DP)
- Control (Type: NO_INTERVENTION): No intermittent preventive treatment (IPT) with dihyroartemisinin-piperaquine (DP) will be given.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TBI Dose De-escalation for Fanconi Anemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Meeting the definition of standard risk or high risk Fanconi anemia as defined in the next two sections:~* Standard risk patients must be \<18 years of age with a diagnosis of Fanconi anemia with aplastic anemia (AA), myelodysplastic syndrome without excess blasts, or high risk genotype as defined below:~  * Aplastic anemia is defined as having at least one of the following when not receiving growth factors or transfusions:~    * platelet count \<20 \* 10\^9/L~   * ANC \<5 \* 10\^8/L~   * Hemoglobin \<8 g/dL~ * Myelodysplastic syndrome (MDS) with multilineage dysplasia with or without chromosomal anomalies~ * High risk genotype (e.g. IVS-4 or exon 14 FANCC mutations, or BRCA1 or 2 mutations)~* High risk patients must have one or more of the following high risk features:~  * Advanced MDS (≥ 5% blast) or acute leukemia~ * Require additional HSCT for graft failure~ * History at any time of systemic fungal or gram negative infection~ * Severe renal disease with a creatinine clearance \<40 mL/min~ * Age \> 18 years~* Very high risk patients must have Advanced MDS (≥ 5% blast) or acute leukemia after initial hematopoietic stem cell transplant (HSCT)~* Patients must have an appropriate source of stem cells. Patients and donors will be typed for HLA-A, B, C and DRB1 using high resolution molecular typing.~* Adequate major organ function including:~  * Cardiac: ejection fraction \>45%~ * Hepatic: bilirubin, AST or ALT, ALP \<5 x normal~ * Karnofsky performance status \>70% or Lansky \>50 (if \< 16 years of age)~* Women of child-bearing age must be using adequate birth control and have a negative pregnancy test.~* Written consent.~Exclusion Criteria:~* Available HLA-genotypically identical related donor in standard risk patients.~* Active central nervous system (CNS) leukemia at time of study enrollment.~* History of squamous cell carcinoma of the head/neck/cervix within previous 2 years.~* Prior radiation therapy that prevents further total body irradiation (TBI).

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment with TBI (Type: EXPERIMENTAL): Patients treated with total body irradiation, Fludarabine, Cyclophosphamide, Bone Marrow Transplantation, Mycophenolate Mofetil, and Sirolimus.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete